![]() |
Name |
Nafuredin
|
Molecular Formula | C22H32O4 | |
IUPAC Name* |
(1R,2R,5R,6S)-5-hydroxy-1-methyl-2-[(1E,3E,5R,7E,9E,11S)-5,7,11-trimethyltrideca-1,3,7,9-tetraenyl]-3,7-dioxabicyclo[4.1.0]heptan-4-one
|
|
SMILES |
CC[C@H](C)/C=C/C=C(\C)/C[C@@H](C)/C=C/C=C/[C@@H]1[C@@]2([C@@H](O2)[C@H](C(=O)O1)O)C
|
|
InChI |
InChI=1S/C22H32O4/c1-6-15(2)11-9-12-17(4)14-16(3)10-7-8-13-18-22(5)20(26-22)19(23)21(24)25-18/h7-13,15-16,18-20,23H,6,14H2,1-5H3/b10-7+,11-9+,13-8+,17-12+/t15-,16-,18+,19+,20-,22+/m0/s1
|
|
InChIKey |
NMEGHQQRWKBPQO-IMNRXHEYSA-N
|
|
Synonyms |
nafuredin; (+)-Nafuredin; 4J6NV9S26K; FT-0554; 224427-79-6; (1R,2R,5R,6S)-5-Hydroxy-1-methyl-2-((1E,3E,5R,7E,9E,11S)-5,7,11-trimethyl-1,3,7,9-tridecatetraen-1-yl)-3,7-dioxabicyclo(4.1.0)heptan-4-one; 3,7-Dioxabicyclo(4.1.0)heptan-4-one, 5-hydroxy-1-methyl-2-((1E,3E,5R,7E,9E,11S)-5,7,11-trimethyl-1,3,7,9-tridecatetraen-1-yl)-, (1R,2R,5R,6S)-; 3,7-Dioxabicyclo(4.1.0)heptan-4-one, 5-hydroxy-1-methyl-2-((1E,3E,5R,7E,9E,11S)-5,7,11-trimethyl-1,3,7,9-tridecatetraenyl)-, (1R,2R,5R,6S)-; UNII-4J6NV9S26K; CHEMBL4162866; (1R,2R,5R,6S)-5-hydroxy-1-methyl-2-[(1E,3E,5R,7E,9E,11S)-5,7,11-trimethyltrideca-1,3,7,9-tetraenyl]-3,7-dioxabicyclo[4.1.0]heptan-4-one
|
|
CAS | 224427-79-6 | |
PubChem CID | 10338591 | |
ChEMBL ID | CHEMBL4162866 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 360.5 | ALogp: | 4.9 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 59.1 | Aromatic Rings: | 2 |
Heavy Atoms: | 26 | QED Weighted: | 0.387 |
Caco-2 Permeability: | -4.705 | MDCK Permeability: | 0.00002260 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.082 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.317 | Plasma Protein Binding (PPB): | 91.95% |
Volume Distribution (VD): | 0.958 | Fu: | 6.64% |
CYP1A2-inhibitor: | 0.14 | CYP1A2-substrate: | 0.164 |
CYP2C19-inhibitor: | 0.284 | CYP2C19-substrate: | 0.809 |
CYP2C9-inhibitor: | 0.199 | CYP2C9-substrate: | 0.958 |
CYP2D6-inhibitor: | 0.69 | CYP2D6-substrate: | 0.899 |
CYP3A4-inhibitor: | 0.844 | CYP3A4-substrate: | 0.264 |
Clearance (CL): | 3.536 | Half-life (T1/2): | 0.177 |
hERG Blockers: | 0.126 | Human Hepatotoxicity (H-HT): | 0.973 |
Drug-inuced Liver Injury (DILI): | 0.933 | AMES Toxicity: | 0.083 |
Rat Oral Acute Toxicity: | 0.05 | Maximum Recommended Daily Dose: | 0.219 |
Skin Sensitization: | 0.258 | Carcinogencity: | 0.038 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.018 |
Respiratory Toxicity: | 0.936 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003160 | ![]() |
0.314 | D0FG6M | ![]() |
0.209 | ||
ENC004902 | ![]() |
0.264 | D0N3NO | ![]() |
0.189 | ||
ENC005399 | ![]() |
0.262 | D0S7WX | ![]() |
0.185 | ||
ENC002137 | ![]() |
0.260 | D0G3PI | ![]() |
0.182 | ||
ENC004901 | ![]() |
0.255 | D02DGU | ![]() |
0.182 | ||
ENC005400 | ![]() |
0.246 | D00DKK | ![]() |
0.182 | ||
ENC005574 | ![]() |
0.246 | D0G8OC | ![]() |
0.180 | ||
ENC004111 | ![]() |
0.245 | D06JPB | ![]() |
0.180 | ||
ENC005422 | ![]() |
0.245 | D0N1TP | ![]() |
0.177 | ||
ENC001850 | ![]() |
0.244 | D0G5CF | ![]() |
0.177 |